Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Positive aspects include increased consumable and recurring revenue, raised revenue guidance for 2025, and promising partnerships. However, concerns arise from inventory charges impacting margins, a widening net loss, and vague management responses in the Q&A. The lack of specific data on CDMO placements and Samsung orders adds uncertainty. While there are growth drivers, the immediate financial health and unclear guidance temper expectations, resulting in a neutral sentiment.
Key Financial Performance
Total fourth quarter revenue $11.3 million, representing 37% year-over-year growth. The growth was driven by strong system placements and exceeded the increased guidance provided in November.
Product revenue Increased 78% in the fourth quarter compared to Q4 2024, primarily driven by the increase in system placements.
Consumable revenue Increased 17% for the full year, reflecting continued strong utilization across the installed base. Consumable growth indicates active system usage and meaningful ROI for customers.
Recurring revenue Increased 15% for the full year and accounted for 53% of total revenue, highlighting the durability and visibility of the business model.
Gross margin Fourth quarter gross margin was impacted by inventory-related charges. Excluding these charges, the gross margin was positive 7%, slightly lower than Q4 2024 due to lower service revenue.
Service revenue $2 million in the fourth quarter, compared to $3 million in Q4 2024. The decrease was due to timing variability in validations.
Product margin Negative 8% in Q4, including a $1.1 million impact from unusable consumable inventory write-off. Excluding this, product margin was positive 4%.
Service margins 22% in Q4 compared to 47% in Q4 2024. The decrease was due to lower service revenue, despite improvements in service productivity and cost reductions.
Net loss $12.5 million in Q4, compared to $9.7 million in Q4 2024. The larger loss was due to inventory charges, lower service margin, and higher interest expense.
Net cash burn $3 million in Q4, with $39 million in cash and investments at year-end.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Growth Direct platform: Samsung Biologics expanded its deployment through a new multisystem order in Q1 2026. Amgen also placed a record multisystem order, deploying systems across North America, Europe, and Asia for environmental monitoring, bioburden, and water testing. A next-generation cloud-native software platform leveraging AI-driven analytics is expected in H2 2026.
Global pharmaceutical market: Partnership with MilliporeSigma is broadening global reach, with customer demo labs established in Europe and Asia. Growth Direct Day events are being expanded to North America and Asia to showcase automation and data management benefits.
Revenue growth: Q4 2025 revenue reached $11.3 million, a 37% YoY growth. Full-year recurring revenue increased by 15%, accounting for 53% of total revenue.
Cost reductions: Significant progress in reducing product costs and improving manufacturing efficiencies. Consumable cost reductions are expected to positively impact margins in 2026.
Strategic priorities: Focus on accelerating system placements, expanding gross margins, innovating new products, and managing cash prudently. Tailwinds include increased automation adoption, data integrity focus, and onshoring of pharmaceutical manufacturing in the U.S.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Inventory-related charges: Fourth quarter gross margin was negatively impacted by inventory-related charges, specifically a $1.1 million write-off of unusable consumable inventory. This issue has been addressed, but it highlights potential risks in inventory management and its impact on margins.
Customer purchase decision uncertainty: There is ongoing uncertainty around the timing and scale of customer purchase decisions, particularly for larger multisystem opportunities. This could impact revenue and system placements.
MilliporeSigma system placement commitment: The low end of the 2026 guidance assumes that MilliporeSigma may not fully satisfy their system placement commitment for the year, which could delay revenue realization.
Service revenue variability: Service revenue is subject to variability due to the timing of validations, which can impact quarterly financial performance.
Gross margin challenges: Gross margins have been impacted by product cost issues and service revenue variability. While improvements are expected, these remain areas of financial risk.
Debt obligations: The company has $25 million of unused capacity under its debt facility, but existing and future indebtedness could impact operational flexibility.
Macroeconomic conditions: General macroeconomic conditions could impact the business and that of its customers, potentially affecting revenue and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company expects total revenue to be in the range of $37 million to $41 million, with 30 to 38 system placements.
Gross Margin Expansion: The company anticipates meaningful gross margin expansion, targeting approximately 20% gross margin for the full year, with performance accelerating in the second half of 2026.
System Placements: Guidance includes expectations for 30 to 38 system placements in 2026, with at least 5 placements in Q1 and 30% of placements occurring in the first half of the year.
Consumable Revenue Growth: Consumable revenue is expected to be slightly higher in Q1 and Q2 2026 compared to Q4 2025, with gradual increases over the remaining quarters.
Service Revenue: Service revenue is projected to be between $2.3 million and $2.6 million in Q1, with slight decreases in Q2 followed by meaningful increases in Q3 and Q4.
New Product Launch: The company plans to release a next-generation cloud-native software platform in the second half of 2026, leveraging AI-driven analytics and insights for enhanced customer value.
Cost Reduction Initiatives: The company expects to realize benefits from material cost reductions and manufacturing efficiency initiatives, with consumable gross margin turning positive in the second half of 2026.
Market Trends and Tailwinds: The company anticipates strong tailwinds from increased adoption of automation, focus on data integrity, advanced manufacturing modalities, and growing investment in U.S. pharmaceutical manufacturing.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is being done to address the gap between placed and validated systems?
A:The gap is attributed to timing variations between system delivery and validation start, depending on customer plans and resources. Management expects the gap to narrow as they work through customer situations, with significant progress expected by the end of the year. They are monitoring the situation and working to keep the gap tight.
Q:What percentage of placed systems are within CDMOs, and how is this space evolving?
A:The exact percentage is not known, but it is sizable. The company has strong relationships with CDMOs like Lonza and Samsung, and they see growth opportunities in this segment. CDMOs benefit from faster line turnarounds and advanced technologies in quality control and manufacturing. Both CDMOs and principal manufacturers are strong segments for the company.
Q:What is the confidence level in achieving a 20% gross margin by 2026, and what are the key drivers?
A:Management is confident due to locked-in product cost reductions with vendors, expected acceleration in Q3 and Q4, and increased service revenues. Volume growth and manufacturing scale are also contributing factors. They expect to exit Q4 with mid-20s or above gross margins.
Q:How will utilization ramp for systems at Samsung and Amgen, and what is the expected consumables pull-through?
A:Validation for Amgen is expected by the end of the year, with recurring revenue contributions likely in 2027. Samsung's timeline is similar. Consumables pull-through has been improving year-over-year in single digits, with potential for more significant increases in 2027 due to large orders and validations.
Q:Can you provide more details on the Samsung multisystem order and its rollout?
A:The order is a next phase of rollout, larger than the initial launch, focused on South Korea with potential global scope. Management expects to grow with Samsung in the future and is discussing additional collaboration opportunities.
Q:What is the difference in process for repeat customers versus new customers?
A:Repeat customers generally move faster through sales and validation processes due to modular validation leveraging prior work. Large orders may have site-based timing variations, but repeat customers typically experience expedited processes.
Q:What is the next-gen cloud-native software platform, and how will it contribute to growth?
A:The platform is a complete rewrite of the application software, offering a modern UI, easier integration, and cloud-based data access. It enables future services like predictive analytics and quality insights, aiming to drive high-margin recurring revenue. Customers are receptive to AI and cloud-enabled solutions.
Q:What are the consumable cost reduction benefits and future plans?
A:Locked-in savings from vendor negotiations will benefit consumables in 2026, with significant reductions in key material costs. The company is also exploring opportunities with Merck MilliporeSigma for long-term cost reductions and plans to use this as a template for future savings.
Q:Review of Unclear Management Responses
A:Management avoided providing the exact percentage of placed systems within CDMOs, citing lack of specific data. Additionally, they did not disclose the specific size of the Samsung multisystem order, only describing it as larger than the initial launch. Details on future monetization of the next-gen cloud-native software platform were also vague, with no specifics on planned services or revenue impact.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI analytics
AI engineer
America Asia
America Europe
Amgen
Biologics deployment
Biosystems Full
Direct Day
Direct platform
Direct system
Europe Asia
Investor Relations
North America
Samsung Biologics
addition
demo lab
deployment Direct
detail
experience
generation
industry
insight
multisystem order
priority
quality manufacturing
record
reminder
rollout
sale funnel
segment
software platform
tailwind
RPID Transcript
Rapid Micro Biosystems, Inc. (RPID) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call shows mixed signals: while there are positive developments like the Millipore JV expansion and potential margin improvements, there are also concerns such as increased net loss, operating expenses, and management's reluctance to provide clear guidance on key issues. The Q&A reveals cautious optimism but also highlights uncertainties. The lack of strong catalysts and the mixed guidance suggest a neutral impact on the stock price over the next two weeks.
Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call presents a mixed outlook. Positive aspects include increased consumable and recurring revenue, raised revenue guidance for 2025, and promising partnerships. However, concerns arise from inventory charges impacting margins, a widening net loss, and vague management responses in the Q&A. The lack of specific data on CDMO placements and Samsung orders adds uncertainty. While there are growth drivers, the immediate financial health and unclear guidance temper expectations, resulting in a neutral sentiment.
Rapid Micro Biosystems, Inc. (RPID) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
Rapid Micro Biosystems, Inc. (RPID) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call revealed positive signs such as a guidance raise due to a large multi-system order, consistent global demand, and improved service margins. Despite a net loss, operating expenses decreased, and cash reserves are strong. The MilliporeSigma partnership and high ROI investments further bolster the outlook. However, management's lack of clarity on some order specifics and onshoring timelines tempers enthusiasm. Overall, the positive factors outweigh the negatives, suggesting a stock price increase in the near term.
RPID Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
